What is GenoFAB?
Based in Fort Collins, Colorado, GenoFAB operates at the intersection of biotechnology and advanced genetic engineering. The company provides a comprehensive catalog of plasmids, ranging from hard-to-source classic variants to proprietary TrueVectors engineered for enhanced scalability and security. By streamlining the supply chain for gene therapy researchers and biomanufacturing professionals, GenoFAB addresses critical bottlenecks in laboratory efficiency. Their service model, which encompasses design, synthesis, purification, and distribution, positions them as a vital infrastructure provider for the rapidly evolving life sciences sector.
How much funding has GenoFAB raised?
GenoFAB has raised a total of $30K across 1 funding round:
Debt
$30K
Debt (2021): $30K with participation from PPP
Key Investors in GenoFAB
PPP
Public-Private Partnership
What's next for GenoFAB?
With this latest infusion of capital, GenoFAB is poised to scale its biomanufacturing infrastructure and broaden its distribution network. The strategic focus will likely shift toward optimizing the production of high-demand genetic materials, ensuring that the company remains at the forefront of the synthetic biology revolution. As the firm transitions through its current growth phase, the emphasis will remain on maintaining rigorous quality standards while expanding its footprint in the global gene therapy market. Future initiatives are expected to prioritize the integration of automated synthesis workflows to meet the increasing demand for reliable, secure, and scalable plasmid solutions.
See full GenoFAB company page
